Acrivon Therapeutics, Inc. (ACRV)
(Delayed Data from NSDQ)
$9.36 USD
+0.67 (7.71%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $9.25 -0.11 (-1.18%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
Cash flow Statements
Fiscal Year End for Acrivon Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -60.39 | -31.17 | -16.24 | -5.31 | NA |
Depreciation/Amortization & Depletion | -2.79 | -0.33 | 0.04 | 0.01 | NA |
Net Change from Assets/Liabilities | 8.14 | -1.53 | 0.33 | 0.32 | NA |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Operating Activities | 12.40 | 2.92 | 1.90 | 2.17 | NA |
Net Cash From Operating Activities | -42.64 | -30.12 | -13.98 | -2.80 | NA |
Property & Equipment | -1.29 | -2.17 | -0.24 | -0.02 | NA |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Investments | 52.01 | -139.51 | 0.00 | 0.00 | NA |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Net Cash from Investing Activities | 50.72 | -141.68 | -0.24 | -0.02 | NA |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.78 | 104.48 | 112.22 | 2.83 | NA |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.06 | NA |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Financing Activities | -2.33 | -2.77 | 0.00 | 0.00 | NA |
Net Cash from Financing Activities | -1.55 | 101.71 | 112.22 | 2.89 | NA |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Net Change In Cash & Equivalents | 6.52 | -70.08 | 98.00 | 0.07 | NA |
Cash at Beginning of Period | 29.91 | 99.99 | 1.99 | 1.92 | NA |
Cash at End of Period | 36.43 | 29.91 | 99.99 | 1.99 | NA |
Diluted Net EPS | -2.74 | -7.56 | -9.32 | NA | NA |
Fiscal Year End for Acrivon Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -35.28 | -16.49 | -60.39 | -41.14 | -26.67 |
Depreciation/Amortization & Depletion | -1.22 | -0.35 | -2.79 | -2.26 | -1.65 |
Net Change from Assets/Liabilities | -1.84 | -3.81 | 8.14 | 3.97 | 2.13 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 7.36 | 3.57 | 12.40 | 9.14 | 5.72 |
Net Cash From Operating Activities | -30.99 | -17.08 | -42.64 | -30.28 | -20.47 |
Property & Equipment | -0.95 | -0.82 | -1.29 | -0.14 | -0.14 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -81.24 | 6.67 | 52.01 | 30.32 | 28.80 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -82.19 | 5.85 | 50.72 | 30.18 | 28.67 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 70.09 | 0.08 | 0.78 | 0.46 | 0.38 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 53.09 | -0.25 | -2.33 | 0.00 | 0.00 |
Net Cash from Financing Activities | 123.18 | -0.17 | -1.55 | 0.46 | 0.38 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 10.00 | -11.41 | 6.52 | 0.36 | 8.58 |
Cash at Beginning of Period | 36.43 | 36.43 | 29.91 | 29.91 | 29.91 |
Cash at End of Period | 46.43 | 25.02 | 36.43 | 30.27 | 38.48 |
Diluted Net EPS | -0.52 | -0.73 | -0.87 | -0.66 | -0.63 |